Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease failed to meet its main goal.
More Stories
‘DJT’ stock continues rally after Elon Musk joins Trump onstage in Pennsylvania
Shares of Trump Media & Technology Group are on pace to extend their winning streak to four days, their longest...
OpenAI has been an asset for Microsoft. Now it could mean risk for the stock.
Oppenheimer downgraded Microsoft’s stock, warning that OpenAI losses could weigh on Microsoft earnings, all while AI revenue might trail expectations.
Brent falls below $80 as oil rally pauses, traders await Israeli response to Iranian missile attack
A rally in oil prices was taking a pause on Tuesday early morning as traders await Israel’s response Iran’s latest...
U.S. trade deficit drops to 5-month low and could add to GDP. Exports hit record high.
The U.S. trade deficit sank almost 11% in August because of lower imports of oil and new cars, potentially giving...
‘I want the calls and letters to stop’: My mother died owing $17,000 in credit-card debt. The creditors want their money. Will I have to sell her house?
“My mom passed away in May from Alzheimer’s. I was her primary caretaker.”
Small businesses have never been more uncertain, and it’s holding back spending, trade group says
Small businesses have never been more uncertain, and it’s impacting their spending plans, a leading trade group said Tuesday.